Cargando…

A review of the role of capecitabine in the treatment of colorectal cancer

5-fluorouracil/leucovorin, with or without oxaliplatin or irinotecan, is the most widely used treatment for the metastatic as well for the adjuvant setting of colorectal cancer. These agents are administered intravenously (by bolus or infusion), thereby causing significant inconvenience to patients....

Descripción completa

Detalles Bibliográficos
Autor principal: Comella, Pasquale
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386354/
https://www.ncbi.nlm.nih.gov/pubmed/18488072
_version_ 1782155228870606848
author Comella, Pasquale
author_facet Comella, Pasquale
author_sort Comella, Pasquale
collection PubMed
description 5-fluorouracil/leucovorin, with or without oxaliplatin or irinotecan, is the most widely used treatment for the metastatic as well for the adjuvant setting of colorectal cancer. These agents are administered intravenously (by bolus or infusion), thereby causing significant inconvenience to patients. Capecitabine, an oral fluoropyrimidine, has been demonstrated to be at least as effective as bolus 5-fluorouracil/leucovorin in terms of time to disease progression, time to treatment failure, and overall survival, but achieves significantly higher response rates and has the advantage of oral administration. In addition, capecitabine has improved tolerability with a significantly lower incidence of stomatitis, nausea, and alopecia than 5-fluorouracil/leucovorin. Clinical trials have shown that combination therapy with capecitabine and either irinotecan or oxaliplatin is effective and well tolerated. The combination of capecitabine plus oxaliplatin, with or without bevacizumab, could represent the new standard of care for metastatic as well as surgically resected high-risk stage II and III colon cancer patients. Some pharmacoeconomic analyses have highlighted that capecitabine plus oxaliplatin results in cost savings compared with 5-fluorouracil/leucovorin plus oxaliplatin.
format Text
id pubmed-2386354
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-23863542008-05-16 A review of the role of capecitabine in the treatment of colorectal cancer Comella, Pasquale Ther Clin Risk Manag Review 5-fluorouracil/leucovorin, with or without oxaliplatin or irinotecan, is the most widely used treatment for the metastatic as well for the adjuvant setting of colorectal cancer. These agents are administered intravenously (by bolus or infusion), thereby causing significant inconvenience to patients. Capecitabine, an oral fluoropyrimidine, has been demonstrated to be at least as effective as bolus 5-fluorouracil/leucovorin in terms of time to disease progression, time to treatment failure, and overall survival, but achieves significantly higher response rates and has the advantage of oral administration. In addition, capecitabine has improved tolerability with a significantly lower incidence of stomatitis, nausea, and alopecia than 5-fluorouracil/leucovorin. Clinical trials have shown that combination therapy with capecitabine and either irinotecan or oxaliplatin is effective and well tolerated. The combination of capecitabine plus oxaliplatin, with or without bevacizumab, could represent the new standard of care for metastatic as well as surgically resected high-risk stage II and III colon cancer patients. Some pharmacoeconomic analyses have highlighted that capecitabine plus oxaliplatin results in cost savings compared with 5-fluorouracil/leucovorin plus oxaliplatin. Dove Medical Press 2007-06 2007-06 /pmc/articles/PMC2386354/ /pubmed/18488072 Text en © 2007 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Comella, Pasquale
A review of the role of capecitabine in the treatment of colorectal cancer
title A review of the role of capecitabine in the treatment of colorectal cancer
title_full A review of the role of capecitabine in the treatment of colorectal cancer
title_fullStr A review of the role of capecitabine in the treatment of colorectal cancer
title_full_unstemmed A review of the role of capecitabine in the treatment of colorectal cancer
title_short A review of the role of capecitabine in the treatment of colorectal cancer
title_sort review of the role of capecitabine in the treatment of colorectal cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386354/
https://www.ncbi.nlm.nih.gov/pubmed/18488072
work_keys_str_mv AT comellapasquale areviewoftheroleofcapecitabineinthetreatmentofcolorectalcancer
AT comellapasquale reviewoftheroleofcapecitabineinthetreatmentofcolorectalcancer